We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Read MoreHide Full Article
Wall Street analysts expect IQVIA Holdings (IQV - Free Report) to post quarterly earnings of $2.63 per share in its upcoming report, which indicates a year-over-year increase of 3.5%. Revenues are expected to be $3.77 billion, up 0.9% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific IQVIA metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Technology & Analytics Solutions' should arrive at $1.52 billion. The estimate indicates a change of +4.4% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Research & Development Solution' will reach $2.08 billion. The estimate suggests a change of -0.9% year over year.
The consensus estimate for 'Revenues- Contract Sales & Medical Solutions' stands at $183.42 million. The estimate indicates a year-over-year change of -3%.
The collective assessment of analysts points to an estimated 'Backlog' of $31.43 billion. Compared to the current estimate, the company reported $30.1 billion in the same quarter of the previous year.
Analysts expect 'Segment Profit- Technology & Analytics Solution' to come in at $365.56 million. Compared to the current estimate, the company reported $335 million in the same quarter of the previous year.
It is projected by analysts that the 'Segment Profit- Contract Sales & Medical Solutions' will reach $15.65 million. Compared to the present estimate, the company reported $13 million in the same quarter last year.
The average prediction of analysts places 'Segment Profit- Research & Development Solutions' at $471.69 million. Compared to the present estimate, the company reported $479 million in the same quarter last year.
IQVIA shares have witnessed a change of -11.1% in the past month, in contrast to the Zacks S&P 500 composite's -0.7% move. With a Zacks Rank #4 (Sell), IQV is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
IQVIA (IQV) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures
Wall Street analysts expect IQVIA Holdings (IQV - Free Report) to post quarterly earnings of $2.63 per share in its upcoming report, which indicates a year-over-year increase of 3.5%. Revenues are expected to be $3.77 billion, up 0.9% from the year-ago quarter.
Over the last 30 days, there has been a downward revision of 0.1% in the consensus EPS estimate for the quarter, leading to its current level. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this timeframe.
Ahead of a company's earnings disclosure, it is crucial to give due consideration to changes in earnings estimates. These revisions serve as a noteworthy factor in predicting potential investor reactions to the stock. Numerous empirical studies consistently demonstrate a strong relationship between trends in earnings estimate revision and the short-term price performance of a stock.
While it's common for investors to rely on consensus earnings and revenue estimates for assessing how the business may have performed during the quarter, exploring analysts' forecasts for key metrics can yield valuable insights.
Bearing this in mind, let's now explore the average estimates of specific IQVIA metrics that are commonly monitored and projected by Wall Street analysts.
Based on the collective assessment of analysts, 'Revenues- Technology & Analytics Solutions' should arrive at $1.52 billion. The estimate indicates a change of +4.4% from the prior-year quarter.
The consensus among analysts is that 'Revenues- Research & Development Solution' will reach $2.08 billion. The estimate suggests a change of -0.9% year over year.
The consensus estimate for 'Revenues- Contract Sales & Medical Solutions' stands at $183.42 million. The estimate indicates a year-over-year change of -3%.
The collective assessment of analysts points to an estimated 'Backlog' of $31.43 billion. Compared to the current estimate, the company reported $30.1 billion in the same quarter of the previous year.
Analysts expect 'Segment Profit- Technology & Analytics Solution' to come in at $365.56 million. Compared to the current estimate, the company reported $335 million in the same quarter of the previous year.
It is projected by analysts that the 'Segment Profit- Contract Sales & Medical Solutions' will reach $15.65 million. Compared to the present estimate, the company reported $13 million in the same quarter last year.
The average prediction of analysts places 'Segment Profit- Research & Development Solutions' at $471.69 million. Compared to the present estimate, the company reported $479 million in the same quarter last year.
View all Key Company Metrics for IQVIA here>>>
IQVIA shares have witnessed a change of -11.1% in the past month, in contrast to the Zacks S&P 500 composite's -0.7% move. With a Zacks Rank #4 (Sell), IQV is expected underperform the overall market performance in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>